SP600125

目录号:S1460 别名: Nsc75890

仅限科研使用

SP600125 (Nsc75890)是一种广谱JNK抑制剂,作用于JNK1、JNK2和JNK3,无细胞试验中IC50分别为40 nM、40 nM和90 nM,比作用于MKK4选择性高10倍,比作用于MKK3、MKK6、PKB和PKCα选择性高25倍,比作用于ERK2、p38、Chk1、EGFR等选择性高100倍。SP600125也是一种广谱的serine/threonine kinases抑制剂,包括Aurora kinase AFLT3TRKA,对应的IC50值为60 nM、90 nM和70 nM。SP600125可抑制自噬而激活细胞凋亡。

SP600125 Chemical Structure

CAS: 129-56-6

规格 价格 库存 购买数量
10mM (1mL in DMSO) RMB 647.05 现货
RMB 573.66 现货
RMB 1204.13 现货
大包装 有超大折扣

今日订购,明日送达 全国免运费 分装免费 分装成小规格产品(单支最小为1mg)
如1支10mg产品可分装为10支1mg产品

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的SP600125发表文献897篇:

产品安全说明书

JNK抑制剂选择性比较

相关JNK产品

生物活性

产品描述 SP600125 (Nsc75890)是一种广谱JNK抑制剂,作用于JNK1、JNK2和JNK3,无细胞试验中IC50分别为40 nM、40 nM和90 nM,比作用于MKK4选择性高10倍,比作用于MKK3、MKK6、PKB和PKCα选择性高25倍,比作用于ERK2、p38、Chk1、EGFR等选择性高100倍。SP600125也是一种广谱的serine/threonine kinases抑制剂,包括Aurora kinase AFLT3TRKA,对应的IC50值为60 nM、90 nM和70 nM。SP600125可抑制自噬而激活细胞凋亡。
特性 SP600125是丝/苏氨酸激酶广谱抑制剂,有效抑制c-Jun 氨基末端激酶(JNK)。
靶点
serine/threonine kinase [1] JNK1 [1]
(Cell-free assay)
JNK2 [1]
(Cell-free assay)
Aurora A [4]
(Cell-free assay)
TrkA [4]
(Cell-free assay)
点击更多
40 nM 40 nM 60 nM 70 nM
体外研究

SP600125是ATP竞争性的c-Jun氨基末端激酶(JNK)选择性抑制剂,IC50为40 nM 到90 nM。SP600125作用于Jurkat T细胞,抑制c-Jun磷酸化,IC50为5 μM 到10 μM。SP600125作用于CD4+细胞, 如从人脐血或外周血分离的Th0细胞,抑制细胞活化和分化,且抑制炎症基因 COX-2, IL-2, IL-10, IFN-γ,和TNF-α的表达, IC50为5 μM 到 12 μM。[1]然而,后期研究显示 SP600125 也抑制香烃受体(AhR)[2] Mps1,[3] 和一系列其他丝/苏氨酸激酶, 包括Aurora 激酶 A, FLT3, MELK,和 TRKA。[4] 20 μM SP600125作用于小鼠beta 细胞 MIN6, 诱导p38 MAPK 磷酸化,和其下游CREB依赖的 启动子的激活。[5] 20 μM SP600125 作用于HCT116细胞, 使有丝分裂停在G2期,且诱导核内复制。[6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Hep3B NWrrfnA{TnWwY4Tpc44hSXO|YYm= NIXJV40yOCEQvF2= NWDMVI1pOSCq M3jMN2Jtd2OtczDheZRweGijZ4mgZY5lKHWycnXneYxifGmxbjDv[kBD\WOuaX6gNUBmgHC{ZYPzbY9vKGmwZIXj[YQh[nliY3XyZY1q\GV? NH3L[IU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUC2NFkzOCd-MUmwOlA6OjB:L3G+
BV-2 MVPGeY5kfGmxbjDBd5NigQ>? MVOyJO69VQ>? NVjoXIlVOSCq NEXnPWRKdmirYnn0d{B1cGViaX7jdoVie2Vib3[gd2JCTkZicnXs[YF{\SCrbjDHcYl5NXS{ZXH0[YQhSlZvMjDj[Yxtew>? NXXMPY9KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm0NFY5OzFpPkG5OFA3QDNzPD;hQi=>
RAW264.7 Mnz0SpVv[3Srb36gRZN{[Xl? MU[xNEDPxE1? NWrxd5hVOTJiaB?= M2rNNmFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyP87:TR?= MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTR7N{SxPEc,OTl2OUe0NVg9N2F-
PC3 M2DPOWZ2dmO2aX;uJGF{e2G7 M2XtdlIxKM7:TR?= NEnQZWoyKGh? NW\BfYl6TGWlcnXhd4V{KHSqZTDNUXAzKGGwZDDNUXA6KGW6cILld5Nqd25? NIXZ[2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOU[zN|k4PSd-MUm2N|M6PzV:L3G+
Plasmodium falciparum HB3 MkXrRY51cWKjY4TldolidCCDc4PhfS=> MljkO|IhcA>? M{LIW2ROW09? NH7aOmZCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhPy57NEOyPEDPxE1? NVfXNWs5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm3N|Q6OTBpPkG5O|M1QTFyPD;hQi=>
Plasmodium falciparum W2 MnzCRY51cWKjY4TldolidCCDc4PhfS=> MnzVO|IhcA>? MkCzSG1UVw>? M3LRWmFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IIfpeIghUUN3MDDv[kA4Njl2M{K4JO69VQ>? NFH2NlI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUezOFkyOCd-MUm3N|Q6OTB:L3G+
Plasmodium falciparum 7G8 MX3BcpRq[mGldHXybYFtKEG|c3H5 NYrVRZo5PzJiaB?= NXf0XnVUTE2VTx?= M{DyfWFvfGmybHHzcY9lcWGuIHHjeIl3cXS7IIfpeIghUUN3MDDv[kAyOCEQvF2= MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTd|NEmxNEc,OTl5M{S5NVA9N2F-
Plasmodium falciparum 3D7 NUDaZ4F6SW62aXLhZ5RmemmjbDDBd5NigQ>? M3z5bVczKGh? MVzEUXNQ NHrIU|lCdnSrcHzhd41w\GmjbDDhZ5Rqfmm2eTD3bZRpKEmFNUCgc4YhOTJwNUi5N{DPxE1? NHq3eWQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUezOFkyOCd-MUm3N|Q6OTB:L3G+
Plasmodium falciparum GB4 MXvBcpRq[mGldHXybYFtKEG|c3H5 NUH6SYJJPzJiaB?= M{PuPWROW09? NV74PFJXSW62aYDsZZNud2SrYXygZYN1cX[rdImge4l1cCCLQ{WwJI9nKDF{LkW4PVPPxE1? NILwVpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUezOFkyOCd-MUm3N|Q6OTB:L3G+
HaCaT NUj0Rm9QTnWwY4Tpc44hSXO|YYm= MomwNlAh|ryP M1;5OVQhcA>? MljySG1UVw>? M3q4XmJtd2OtczD0bIUhXE6ILd8xMYlv\HWlZXVCpGN[WDSIMUJCpJRz[W6|Y4LpdJRqd25? NVnOO5lFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NVI{PDlpPkG5PFEzOzR7PD;hQi=>
HaCaT NVqzeVI6TnWwY4Tpc44hSXO|YYm= MnLGNlAh|ryP MmW5NlQhcA>? MYrEUXNQ NHS1fWxDdG:la4OgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iClLVr1ckBxem:2ZXnu NU\sbWVDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm4NVI{PDlpPkG5PFEzOzR7PD;hQi=>
A549 MU\GeY5kfGmxbjDBd5NigQ>? NXP1fWJ[OjBizszN M4LEUFEhcA>? MonWTY5pcWKrdHnvckBw\iCWUFGtbY5lfWOnZDDNUXAuOiCjbnSgeU1RSSCneIDy[ZN{cW:w MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR7MkG3OUc,OjB2OUKxO|U9N2F-
PC12 MV\GeY5kfGmxbjDBd5NigQ>? NUXZVWsyOTBizszN MnH5OUBp MUfEUXNQ NV\4fohmSWO2aY\heIlwdiCxZjDOdoYzN0GURTDhd5Nme3OnZDDhd{BJVy1zIIDyc5RmcW5iaX7keYN1cW:wIIDy[ZRz\WG2ZXSge4l1cCCSREm4NFU6 M2rzZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzM{S1Olg2Lz5{MUO0OVY5PTxxYU6=
PC12 MUDGeY5kfGmxbjDBd5NigQ>? MXWxNEDPxE1? NGjO[FQ2KGh? M2XEVmROW09? MkHrRYN1cX[jdHnvckBw\iCQcn[yM2FTTSCjc4Pld5Nm\CCjczDIU{0yKHC{b4TlbY4hcW6mdXP0bY9vKHC{ZYTy[YF1\WRid3n0bEBWODF{Nh?= MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2NU[4OUc,OjF|NEW2PFU9N2F-
PC12 MV;GeY5kfGmxbjDBd5NigQ>? NWL0PIhUOTBizszN NH\yUng2KGh? M2ruVWROW09? NH;udpBC[3SrdnH0bY9vKG:oIF7y[lIwSVKHIHHzd4V{e2WmIHHzJGhQNTFicILveIVqdiCrbnT1Z5Rqd25icILleJJm[XSnZDD3bZRpKFOSNkCwNVI2 MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTN2NU[4OUc,OjF|NEW2PFU9N2F-
PC12 NXX3U5RLTnWwY4Tpc44hSXO|YYm= NGHPe|IyOCEQvF2= M{WwT|UhcA>? NWfYN2lXTE2VTx?= MUHBZ5RqfmG2aX;uJI9nKE6{ZkKvRXJGKGG|c3Xzd4VlKGG|IFjPMVEheHKxdHXpckBqdmS3Y4Tpc44heHKndILlZZRm\CC5aYToJHNDOjB|NUiw NFzCSXA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUO0OVY5PSd-MkGzOFU3QDV:L3G+
B16-F10 M1fQWGZ2dmO2aX;uJGF{e2G7 NFLv[2gyKGh? MWXJcohq[mm2aX;uJI9nKFSQRj3hcJBp[S2rbnT1Z4VlKGNvSmXOJJBpd3OyaH;yfYxifGmxbh?= NGW2[GM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUixOVY{PCd-MkG4NVU3OzR:L3G+
LoVo M1rNdGZ2dmO2aX;uJGF{e2G7 M3z5dVEh|ryP MWOxJIg> NWj0TFFLUW6qaXLpeIlwdiCxZjDQS2UzNWmwZIXj[YQh\XiycnXzd4lwdiCxZjD1VGEh[W6mIF3NVE06KHOrZ37p[olk[W62bIm= NX7YbpFNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4OVk1PzlpPkKxPFU6PDd7PD;hQi=>
LoVo MnvJSpVv[3Srb36gRZN{[Xl? MYixJO69VQ>? NH7lc44yKGh? NGXwUIFDdG:la4PQS2UzNWmwZIXj[YQh[2WubDDtbYdz[XSrb36gd4lodmmoaXPhcpRtgQ>? MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTh3OUS3PUc,OjF6NUm0O|k9N2F-
THP-1 NFHNPGJHfW6ldHnvckBCe3OjeR?= M4TWXlkxKG6P NFTXbHU{OCCvaX6= Mn\4TY5pcWKrdHnvckBw\iC2aYPzeYUh\mGldH;yJIV5eHKnc4Ppc44> M4\0UlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUSwNFU6Lz5{Mkm0NFA2QTxxYU6=
PC3 MlexSpVv[3Srb36gRZN{[Xl? MnfoNlUh|ryP MVyyOEBp NXjUcHdwUW6qaXLpeIlwdiCxZjDBVE0yKGGwZDDwNlEhdHWlaX\ldoF{\SCjY4Tpeol1gSCrbnT1Z4VlKGK7IGOxO|lFKFCUTB?= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzF4Mk[1Nkc,OjNzNkK2OVI9N2F-
SH-SY5Y MlXsSpVv[3Srb36gRZN{[Xl? NX3kdJRkOTBizszN MmDINUBp Ml2zSG1UVw>? NV7zfIk5VmW3cn;wdo91\WO2aY\lJIFkfGm4aYT5JIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCxZjDhcol{d227Y3nuMYlv\HWlZXSgZ4VtdCCmZXH0bC=> NW\rPVQ2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVg6OTRpPkKzOFk5QTF2PD;hQi=>
SH-SY5Y NEjRd2tMcW6jc3WgRZN{[Xl? M3LoTFExKM7:TR?= MYGxJIg> MoGxSG1UVw>? MlHXTY5pcWKrdHnvckBw\iCMTluzJIF{e2W|c3XkJIF{KGKub3PrZYRmKG:oIHHubZNwdXmlaX6tbY5lfWOnZDDjMYp2diCyaH;zdIhwenmuYYTpc44h[XRic3XyO|M> M3zKPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|NEm4PVE1Lz5{M{S5PFkyPDxxYU6=
RAW264.7 M3\rSGZ2dmO2aX;uJGF{e2G7 M36xWlExKM7:TR?= NITtO4gzPCCq NVHBbVlWSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGlNNTGkZYThJJJmdGWjc3W= MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MUC3PEc,OjN5OUGwO|g9N2F-
RAW264.7 MYDGeY5kfGmxbjDBd5NigQ>? NHLue2wyOCEQvF2= NWLqdGMxOjRiaB?= NXnvcpp{SW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGxRWy2rbnT1Z4VlKGmQT2Og[ZhxemW|c3nvci=> MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzd7MUC3PEc,OjN5OUGwO|g9N2F-
RAW264.7 MYnGeY5kfGmxbjDBd5NigQ>? MXmxNEDPxE1? MUKyJIg> M1zMU2FvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgZZN{\XO|ZXSgZZMhcW6qaXLpeIlwdiCxZjDMVHMucW6mdXPl[EBPVyCycn;keYN1cW:w M1LpdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ|N{mxNFc5Lz5{M{e5NVA4QDxxYU6=
A549 NIrHSHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoriNlAh|ryP Mon6O|IhcA>? MlPQSG1UVw>? MnXtVoFxcWRiYX7kJJBwfGWwdDDpcohq[mm2aX;uJI9nKGOnbHygdJJwdGmoZYLheIlwdg>? NUXIOoVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5NVI5PDBpPkKzPVEzQDRyPD;hQi=>
RAW264.7 NIC5S3RCdnSraX7mcIFudWG2b4L5JIF{e2G7 NITzVmxCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgUm8heHKxZIXjeIlwdiC{ZXzheIl3\SC2bzDjc451em:uLDDJR|UxKD1iMUeg{txONg>? M3HCb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OEOxO|k5Lz5{MkizNVc6QDxxYU6=
BMMC NIXiWlBHfW6ldHnvckBie3OjeR?= NWDUdXZVOSC2bzCyNEB2VQ>? NF:1SXU4KGSjeYO= NHzOR|BKdmirYnn0bY9vKG:oIGLBUmtNN01vQ2PGMZN1cW23bHH0[YQhd3O2ZX;jcIF{fG:pZX7ld4l{KGmwIFnDVkBud3W|ZTDCUW1EKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBVWkGSIIDvd4l1cX[nIH31cJRqdnWlbHXheIVlKGOnbHzzJIF1KDFidH:gNlAhfU1iaX7jeYJifGWmIH\vdkA4KGSjeYOgZpkhdGmpaISgcYlkem:|Y3;wfS=> NX[wS2tORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzPVc3PzZpPkK1N|k4Pjd4PD;hQi=>
A673 MUHxTHRUKGG|c3H5 MV;xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>? Mn\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-37 M332OZFJXFNiYYPzZZk> NWjhOHMzeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IFLUMVM4KGOnbHzz MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH MXzxTHRUKGG|c3H5 NVXyOmdMeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM> NFjnWIk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 NHT1N|hyUFSVIHHzd4F6 MWfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJzNkSzJINmdGy| MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 M3L6UpFJXFNiYYPzZZk> MnPldWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?= NE\6TGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
SK-N-MC MVzxTHRUKGG|c3H5 NWP4fHBjeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> M3P4elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1 NUTZbmdseUiWUzDhd5NigQ>? M1vQSZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz M33KVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 NGX4RZdyUFSVIHHzd4F6 NGr6RlNyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Assay
Methods Test Index PMID
Western blot p-JNK p-IGF1R / IGF1R / p-Akt / Akt / p-ERK / ERK p-Src / Src p-c-Jun / c-Jun / pJNK / JNK Survivin / Bcl-2 / PARP p-FADD / FADD / p-c-Jun / c-Jun 25226534 27176481 22870247 21859840
Immunofluorescence AIF / Endo G E-cadherin / β-catenin α-catenin / Actin 21738692 21030692
Growth inhibition assay Cell viability (U-87 MG) Cell viability (A549) 27176481 24944614
体内研究

SP600125按15 mg/kg或30 mg/kg剂量作用于小鼠,显著抑制脂多糖(LPS)诱导的TNF-α表达和CD3抗体诱导的CD4+ CD8+胸腺细胞凋亡。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[4]

  • 体外激酶实验:

    根据测量放射性磷酸转移到底物中的量,而测定SP600125作用于激酶的效果,包括MPS1, JNK, 和 Aurora 激酶 A。使用5 nM MPS1 重组蛋白在50 mM HEPES pH 7.5,2.5 mM MgCl2,1 mM MnCl2,1 mM DTT,3 μM NaVO3, 2 mM β-甘油磷酸,0.2 mg/mL BSA, 200 μM P38-βtide 底物-肽(KRQADEEMTGYVATRWYRAE),和含1.5 nM33P-γ-ATP的8 μM ATP中测量MPS1活性。使用1:3 稀释的(从30 μM 稀释成 1.5 nM) SP600125进行实验,然后测定IC50值。

细胞实验:

[4]

  • Cell lines: HCT116, A2780, 和U2OS细胞
  • Concentrations: 0-5 μM
  • Incubation Time: 72小时
  • Method:

    细胞接种在384孔板上。实验第一天,用SP600125处理细胞72小时,然后通过 CellTiter-Glo 实验处理实验板。测定与对照组相比,实验组的抑制活性,计算抑制增殖的IC50值。

动物实验:

[1]

  • Animal Models: 雌性 CD-1小鼠LPS/TNF模型
  • Dosages: 15或30 mg/kg
  • Administration: 静脉注射或口服处理

溶解度(25°C)

体外

体内

从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O

2mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 220.23
化学式

C14H8N2O

CAS号 129-56-6
储存条件 3年 -20°C 粉状
2年 -80°C 溶于溶剂

动物体内配方计算器(澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)

mg/kg g μL

第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)

% DMSO % % Tween 80 % ddH2O
%DMSO %

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于μL DMSO溶液(母液浓度mg/mL,:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);

体内配方配制方法:μL DMSO母液,加入μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入μL ddH2O,混匀澄清。

体内配方配制方法:μL DMSO母液,加入μL Corn oil,混匀澄清。

注意:1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

摩尔浓度计算器

质量 浓度 体积 分子量

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

* 必填项

请输入您的姓名
请输入您的邮箱地址 请输入一个有效的邮箱地址
请写点东西给我们

常见问题及建议解决方法

问题 1:
how to reconstitute the inhibitor for in vivo studies?

回答:
S1460 can be dissolved in 5% DMSO/corn oil at 5 mg/ml as a clear solution for injection. The inhibitor dissolved in vehicle 30% PEG400/0.5% Tween80/5%Propylene glycol, at 30mg/ml is a suspension and can be used for oral administration.